股 票 研 究 公 司 更 新 报 告 证 券 研 究 报 告 ——交通银行 2024 年三季报点评 [table_Authors] 刘源(分析师) 021-38677818 liuyuan023804@gtjas.com 登记编号 S0880521060001 本报告导读： 交通银行 24Q3 营收及净利润增速小幅超出预期，息差管控颇有成效，资产质量稳 中向好。上调目标价至 8.4 元，维持增持评级。 投资要点： [Table_Summary] 投资建议：2024 年以来交通银行强调高质量发展，重"量"更重"质"。 相较规模扩张更关注息差平稳，同时资产质量在经历了三年"资产 质量攻坚战"、"资产质量巩固年"后进入"贷投后管理年"，核心指 标持续向好。根据三季报表现及降息后未来存贷款重定价情况，调 整公司 2024-2026 年净利润增速预测为 0.4%、0.5%、2.2%，对应 BVPS 为 12.97(-0.11)、13.93(+0.03)、14.74(-0.03)元/股。考虑到一揽 子稳经济政策密集出台，利好银行风险缓释和信贷需求恢复，推动 板块估值回升，上调目标价至 8.4 元，对应 2024 年 0 ...

股 票 研 究 证 券 研 究 报 告 ——2024 年三季报点评 IVD 产线和国际市场实现较快增长 普门科技(688389) [Table_Industry] 医药/必需消费 | --- | --- | --- | |----------|-----------------------------------|-----------------------| | | | | | | [table_Authors] 丁丹 ( 分析师 ) | 赵峻峰 ( 分析师 ) | | | 0755-23976735 | 0755-23976629 | | | dingdan@gtjas.com | zhaojunfeng@gtjas.com | | 登记编号 | S0880514030001 | S0880519080017 | 本报告导读： 公司 IVD 产线稳健增长，其中国际市场快速增长，临床医疗和皮肤医美业务短期承 压，有望逐步恢复。维持增持评级 投资要点： 股票研究 /[Table_Date] 2024.11.04 | --- | --- | --- | |--------------------------- ...

股 票 研 究 ——潮宏基 2024 年三季度业绩点评 | --- | --- | |----------|-------------------------------------| | | | | | [table_Authors] 刘越男 ( 分析师 ) | | | 021-38677706 | | | liuyuenan@gtjas.com | | 登记编号 | S0880516030003 | | --- | |------------------| | | | | | | | | | 021-38038344 | | suying@gtjas.com | | S0880522110001 | 本报告导读： 2024Q3 业绩符合预期，公司聚焦品牌优势产品，整体表现强于珠宝行业大盘；渠道 激励与组织架构逐步捋顺，成长空间值得期待。 投资要点： [Table_Summary] 业绩略低于预期，维持"增持"评级。考虑到金价持续上行，克重 黄金品类终端动销承压、加盟商拿货意愿疲弱，且公司女包业务复 苏节奏较慢，下调 2024-2026 年 EPS 分别为 0.44/0.51/0.57 元（原值 0.46/ ...

国泰君安版权所有发送给上海东方财富金融数据服务有限公司.东财接收研报邮箱.ybjieshou@eastmoney.com p1 股 票 研 究 公 司 更 新 报 告 证 券 研 究 报 告 ——2024 年三季报点评 股票研究 /[Table_Date] 2024.11.03 业绩基本符合预期，销售费用率持续优化 济川药业(600566) [Table_Industry] 医药/必需消费 | --- | --- | --- | --- | --- | --- | --- | --- | |----------|-----------------------------------|--------------|----------------------------|-------|-------|-------|-------| | | | | | | | | | | | [table_Authors] 丁丹 ( 分析师 ) | 唐玉青 ( | 研究助理 | | ) | | | | | 0755-23976735 | 021-38031031 | | | | | | | | dingdan@gtjas.c ...

股 票 研 究 公 司 更 新 报 告 证 券 研 究 报 告 | --- | --- | --- | --- | --- | --- | |--------------------------------------|--------|-------|-------|-------|-------| | [Table_Finance] 财务摘要（百万元） | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业收入 | 962 | 1,176 | 1,217 | 1,376 | 1,528 | | (+/-)% | 8.4% | 22.2% | 3.5% | 13.1% | 11.0% | | 净利润（归母） | 76 | 128 | 136 | 159 | 183 | | (+/-)% | -20.0% | 68.9% | 6.0% | 17.3% | 14.7% | | 每股净收益（元） | 0.43 | 0.73 | 0.78 | 0.91 | 1.05 | | 净资产收益率 (%) | 11.1% | 16.2% | 15.0% | 15.4% | 15.4% | ...

股 票 研 究 公 司 更 新 报 告 证 券 研 究 报 告 国泰君安版权所有发送给上海东方财富金融数据服务有限公司.东财接收研报邮箱.ybjieshou@eastmoney.com p1 ——成都银行 2024 年三季报点评 股票研究 /[Table_Date] 2024.11.03 | --- | |-----------------------------------| | | | [table_Authors] 刘源 ( 分析师 ) | | 021-38677818 | | liuyuan023804@gtjas.com | | 登记编号 S0880521060001 | 本报告导读： 成都银行 2024 年三季报营收及净利润增速符合预期，规模保持较高增速，息差韧性 小幅超出预期，资产质量稳中向好。维持目标价 18.65 元，维持增持评级。 投资要点： [Table_Summary] 投资建议：成都银行位于重大国家战略叠加实施的重点区域，信贷 需求相对强劲，规模增速领先同业。在巩固政务金融传统优势的同 时，公司积极发展实体业务、零售消费贷和财富管理，布局长远。 根据三季报表现及降息后未来存贷款重定价 ...

国泰君安版权所有发送给上海东方财富金融数据服务有限公司.东财接收研报邮箱.ybjieshou@eastmoney.com p1 | --- | |-------| | | | | | | 公 司 更 新 报 告 证 券 研 究 报 告 ——奥锐特 2024 年三季报点评 | --- | |-----------------------------------| | | | | | | | [table_Authors] 丁丹 ( 分析师 ) | | 0755-23976735 | | dingdan@gtjas.com | | S0880514030001 | | --- | --- | --- | --- | --- | --- | |-----------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | 010-83939773 | | | | | | | wuhan024878@gtjas.com | | | | | | | S0880523080005 | | | | | | 本报告导 ...

Investment Rating - Maintains an "Overweight" rating with a target price of 119.37 RMB [2][3][4] Core Views - The company's aortic business is under pressure due to price adjustments, but its medium-to-long-term competitiveness remains intact [2] - Peripheral products are expected to accelerate market penetration through centralized procurement, contributing to incremental growth [2] - The impact of price adjustments is expected to be fully absorbed by Q3 2025, and the company's competitiveness in the aortic field is likely to remain strong [3] - The company's overseas business is expected to accelerate following the acquisition of OMD [3] Financial Performance - Q1-Q3 2024 revenue reached 970 million RMB, a YoY increase of 9.1%, with net profit attributable to shareholders of 553 million RMB, up 42.5% YoY [3] - Q3 2024 revenue was 182 million RMB, a YoY decrease of 31.7%, with net profit attributable to shareholders of 150 million RMB, up 37.6% YoY [3] - Adjusted EPS forecasts for 2024-2026 are 3.86/4.27/6.19 RMB, down from previous estimates of 5.19/5.98/7.54 RMB [3] Product and Market Dynamics - Aortic stent prices were adjusted in August and September 2024, with thoracic stent prices reduced by approximately 40% and abdominal stent prices by 20%-35% [3] - The company's peripheral products, including venous stents and vena cava filters, have been approved and are expected to benefit from centralized procurement [3] - New products such as Cratos, AegisⅡ, and Hector are in development and expected to enhance the company's competitiveness in the aortic field [3] Valuation and Market Data - The company's current price is 98.06 RMB, with a 52-week price range of 79.81-206.98 RMB [4][5] - Total market capitalization is 12,087 million RMB, with 123 million shares outstanding [5] - The company's P/E ratio for 2024 is 25.41, with a target P/E of 28X for 2025 [3][4] Financial Forecasts - Revenue for 2024E is projected at 1,161 million RMB, with a YoY decrease of 2.2%, while 2025E and 2026E revenues are expected to grow by 22.2% and 38.8%, respectively [9] - Net profit attributable to shareholders for 2024E is forecasted at 476 million RMB, with 2025E and 2026E profits expected to grow by 10.7% and 44.9%, respectively [9] - ROE for 2024E is projected at 11.4%, increasing to 15.8% by 2026E [9] Industry Comparison - The company's valuation is compared to peers such as Xishan Technology, United Imaging Healthcare, and SonoScape, with an average P/E ratio of 38 for 2023A, 37 for 2024E, and 28 for 2025E [11]

股 票 研 究 公 司 更 新 报 告 国泰君安版权所有发送给上海东方财富金融数据服务有限公司.东财接收研报邮箱.ybjieshou@eastmoney.com p1 ——2024 年三季报点评 赛立奇销售超预期，商业化成果初显 智翔金泰-U(688443) [Table_Industry] 医药/必需消费 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------|-------------------|-----------------|----------------------------|----------------------------|-------|-------|-------|-------| | | | | | | | | | | | | 丁丹 ( 分析师 ) | [table_Authors] | 甘坛焕 ( 分析师 ) | 唐玉青 ( 研究助理 | | ) | | | | | 0755-23976735 | | 021-38675855 | 021-38031031 | | | | | | | ding ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 59.16 RMB, up from the previous target of 48.80 RMB [2][3] Core Views - The company faces short-term pressure due to external consumption environment, with steady growth in outpatient visits but pressure on average spending per customer [3] - The dental implant business is growing through volume expansion despite price reductions, while the consumer dental segment remains under pressure [3] - The "Dandelion" branch hospitals are growing rapidly, contributing significantly to revenue, and new hospital expansions are progressing steadily [3][8] Financial Performance - In Q1-Q3 2024, the company achieved revenue of 2.233 billion RMB (+2.21% YoY), with net profit attributable to shareholders of 498 million RMB (-2.63% YoY) [8] - Gross margin for Q1-Q3 2024 was 41.82% (-0.77 pct YoY), and net profit margin was 26.95% (-1.07 pct YoY) [8] - The company's total market capitalization is 22.525 billion RMB, with a current price of 50.36 RMB [5] Operational Highlights - Outpatient visits in Q1-Q3 2024 reached 2.65 million (+6.5% YoY), with 2.29 million visits in the home province (+4.5% YoY) and 360,000 visits outside the province (+21.7% YoY) [8] - Dental implant revenue grew to 384 million RMB (+11.7% YoY), with the number of implants increasing by 30% YoY [8] - The "Dandelion" hospitals contributed 523 million RMB in revenue (+19% YoY), accounting for 23% of total revenue, with a gross margin of 21% and a net profit margin of 12.9% [8] Expansion Plans - The company plans to open 8 new "Dandelion" hospitals in 2024, with 3 already delivered and 5 expected by year-end [8] - The Zijin Port hospital is expected to start trial operations by the end of 2024, and the new West City hospital is expected to complete relocation by 2025 [8] - The Yiwu General Hospital is expected to open between late 2024 and early 2025, with plans to open 5-8 new "Dandelion" hospitals in 2025 [8] Financial Forecasts - Revenue for 2024E is forecasted at 2.918 billion RMB (+2.5% YoY), with net profit attributable to shareholders of 521 million RMB (+4.0% YoY) [9] - EPS for 2024E is projected at 1.16 RMB, with ROE expected to be 12.1% [9] - The company's P/E ratio for 2024E is 43.26x, and the P/B ratio is 5.24x [9]